Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPC6 | Q9Y210 | 20/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30439661 | 1.00 | TRPC6 (0.63) | TRPC6 | |
| SCHEMBL21288378 | 0.92 | TRPC6 (0.62) | TRPC6 | |
| SCHEMBL29773977 | 0.89 | TRPC6 (0.56) | TRPC6 | |
| SCHEMBL21081312 | 0.89 | TRPC6 (0.56) | TRPC6 | |
| SCHEMBL30439769 | 0.87 | KDM4E (0.50) | TRPC6 | |
| SCHEMBL29011972 | 0.87 | KDM4E (0.50) | TRPC6 | |
| SCHEMBL1807109 | 0.86 | TRPC6 (0.52) | TRPC6 | |
| SCHEMBL21245878 | 0.85 | ALOX5AP (0.52) | TRPC6 | |
| SCHEMBL21045846 | 0.84 | TRPC6 (0.66) | TRPC6 | |
| SCHEMBL26485994 | 0.84 | TRPC6 (0.47) | TRPC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3752499-B1 | INHIBITORS OF TRPC6 | BOEHRINGER INGELHEIM INT (DE) | 2024-03-27 | — | — | EP | disclosed |
| CN-111868055-B | Inhibitors of TRPC6 | 勃林格殷格翰国际有限公司 | 2024-03-08 | — | — | CN | disclosed |
| CN-111770918-B | Inhibitors of TRPC6 | 勃林格殷格翰国际公司 | 2024-02-27 | — | — | CN | disclosed |
| US-RE49699-E1 | Inhibitors of TRPC6 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2023-10-17 | — | — | US | disclosed |
| US-RE49699-E1 | Inhibitors of TRPC6 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2023-10-17 | — | — | US | disclosed |
| US-RE49699-E1 | Inhibitors of TRPC6 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2023-10-17 | — | — | US | disclosed |
| CN-111527078-B | Pyridinecarbonyl derivatives and their therapeutic use as TRPC6 inhibitors | 勃林格殷格翰国际公司 | 2023-06-02 | — | — | CN | disclosed |
| EP-3700902-B1 | INHIBITORS OF TRPC6 | BOEHRINGER INGELHEIM INT (DE) | 2023-03-08 | — | — | EP | disclosed |
| US-11485740-B2 | Inhibitors of TRPC6 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2022-11-01 | — | — | US | disclosed |
| EP-3786160-B1 | PYRIDINE DERIVATIVES AND THERAPEUTIC USES THEREOF AS TRPC6 INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2022-07-13 | — | — | EP | disclosed |
| CN-111770918-A | Inhibitors of TRPC6 | 勃林格殷格翰国际公司 | 2020-10-13 | — | — | CN | disclosed |
| US-10800757-B2 | Inhibitors of TRPC6 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-10-13 | — | — | US | disclosed |
| US-10800757-B2 | Inhibitors of TRPC6 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-10-13 | — | — | US | disclosed |
| CN-111527078-A | Pyridinecarbonyl derivatives and their therapeutic use as TRPC6 inhibitors | 勃林格殷格翰国际公司 | 2020-08-11 | — | — | CN | disclosed |
| WO-2019161010-A1 | INHIBITORS OF TRPC6 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2019-08-22 | — | — | WO | disclosed |
| WO-2019158572-A1 | INHIBITORS OF TRPC6 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2019-08-22 | — | — | WO | disclosed |
| US-20190169168-A1 | INHIBITORS OF TRPC6 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2019-06-06 | — | — | US | disclosed |
| US-20190169168-A1 | INHIBITORS OF TRPC6 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2019-06-06 | — | — | US | disclosed |
| US-20190169167-A1 | INHIBITORS OF TRPC6 | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2019-06-06 | — | — | US | disclosed |
| US-20190169167-A1 | INHIBITORS OF TRPC6 | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2019-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190169168-A1 | INHIBITORS OF TRPC6 | TRPC6, TRPC1, TRPC7 | TRPC6 1/4885 |
| US-11485740-B2 | Inhibitors of TRPC6 | TRPC6, TRPC1, TRPC4 | TRPC6 1/4885 |
| US-20190169167-A1 | INHIBITORS OF TRPC6 | TRPC6, TRPC1, TRPC7 | TRPC6 1/4885 |
| US-10800757-B2 | Inhibitors of TRPC6 | TRPC6, TRPC1, TRPC7 | TRPC6 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.